Literature DB >> 1371206

Choice of palliation for malignant hilar biliary obstruction.

E C Lai1, K M Chu, C Y Lo, S T Fan, C M Lo, J Wong.   

Abstract

Clinical data from 50 consecutive patients with unresectable hilar tumors situated at or proximal to the common hepatic duct were retrospectively analyzed to aid in the selection of appropriate palliative measures. Thirty-four patients had cholangioenteric bypass (CEB) to either left (28 patients), right (3 patients), or both (3 patients) intrahepatic ductal systems. Sixteen patients had nonoperative drainage (NOD) established either endoscopically (4 patients), percutaneously (9 patients), or using a combined endoscopic-percutaneous approach (3 patients). When compared with patients with CEB, patients with NOD had more frequent medical problems (p less than 0.03) and lower serum albumin levels on admission (p less than 0.03). While comparable postprocedural complications (13 CEB patients versus 4 NOD patients) were observed, patients with NOD had a significantly higher hospital mortality (9 CEB patients versus 9 NOD patients, p less than 0.05). Excluding the 12 patients (6 CEB patients versus 6 NOD patients) who died within 30 days after drainage, the quality of survival of the remaining 38 patients was analyzed with reference to 6 objective parameters. Although patients with NOD had significantly more frequent admissions relating to their catheters (p less than 0.02), there was no qualitative difference in the survival rate between the two groups of patients. For selected high-risk patients with limited life expectancy, NOD should be offered. However, additional prospective studies are required to decide the best choice of palliation for patients who are not at such high risk.

Entities:  

Mesh:

Year:  1992        PMID: 1371206     DOI: 10.1016/0002-9610(92)90102-w

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  13 in total

1.  Cholangiocarcinoma.

Authors:  Prabhleen Chahal; Todd H Baron
Journal:  Curr Treat Options Gastroenterol       Date:  2005-12

Review 2.  [Palliative bypass surgery].

Authors:  A Wojtyczka; T Moesta; C Kuntz; T Lehnert
Journal:  Chirurg       Date:  2006-03       Impact factor: 0.955

3.  Surgical palliation for unresectable hilar cholangiocarcinoma.

Authors:  S Connor; S J Wigmore; K K Madhavan; R W Parks; O J Garden
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

4.  A simplified percutaneous hepatogastric drainage technique for malignant biliary obstruction.

Authors:  L Tipaldi
Journal:  Cardiovasc Intervent Radiol       Date:  1995 Sep-Oct       Impact factor: 2.740

Review 5.  Advances in endoscopic retrograde cholangiopancreatography for the treatment of cholangiocarcinoma.

Authors:  Dushant S Uppal; Andrew Y Wang
Journal:  World J Gastrointest Endosc       Date:  2015-06-25

Review 6.  Cholangiocarcinoma and malignant bile duct obstruction: A review of last decades advances in therapeutic endoscopy.

Authors:  Helga Bertani; Marzio Frazzoni; Santi Mangiafico; Angelo Caruso; Mauro Manno; Vincenzo Giorgio Mirante; Flavia Pigò; Carmelo Barbera; Raffaele Manta; Rita Conigliaro
Journal:  World J Gastrointest Endosc       Date:  2015-06-10

7.  Palliative decompression of obstructive hilar malignancies utilizing an extrahilar biliary approach.

Authors:  S Yilmaz; V Kirimlioglu; D A Katz; M Caglikulekci; M Yilmaz
Journal:  Dig Dis Sci       Date:  2000-08       Impact factor: 3.199

8.  [Is there a nonsurgical therapeutic approach to cholangiocellular carcinomas?].

Authors:  M Fuchs; W Schepp
Journal:  Chirurg       Date:  2006-04       Impact factor: 0.955

9.  Optimal biliary drainage for inoperable Klatskin's tumor based on Bismuth type.

Authors:  Sang Hyub Lee; Joo Kyung Park; Won Jae Yoon; Jun Kyu Lee; Ji Kon Ryu; Yong Bum Yoon; Yong-Tae Kim
Journal:  World J Gastroenterol       Date:  2007-08-07       Impact factor: 5.742

10.  Guidelines for palliative surgery of cholangiocarcinoma.

Authors:  H Witzigmann; H Lang; H Lauer
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.